Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-use MK-8342B vaginal ring pharmacokinetics and pharmacodynamics study
NL-OMON43028Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ENG-E2 in contraception and primary dysmenorrhea (PD), sponsored by Merck & Co. Primary endpoints: Ovarian function pharmacodynamics, Pharmacokinetics of etonogestrel, estradiol, and estrone and 1 more. Started Jun 2016; status: active, not recruiting.
02
Drugs
ENG-E2
03
Conditions
contraceptionprimary dysmenorrhea (PD)
Beyond the preview
Go deeper on NL-OMON43028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43028.